HOOKIPA Pharma Inc. has announced an Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $50,000,000 of common stock. The agreement permits HOOKIPA Pharma to offer and sell its common stock through Jefferies, acting as a sales agent or principal. The previous sales agreement with SVB Securities LLC has been terminated, and no further sales will occur under that agreement. HOOKIPA Pharma's common stock is listed on the Nasdaq Capital Market under the symbol 'HOOK,' with a last reported sale price of $4.91 per share as of August 7, 2024. The sales are to be made in 'at the market offerings,' and Jefferies will receive a commission of 3.0% of the gross proceeds from any sales made under the agreement. Jefferies will also be considered an 'underwriter' within the meaning of the Securities Act, and will receive underwriting commissions or discounts. HOOKIPA Pharma has agreed to indemnify Jefferies against certain liabilities, including those under the Securities Act. The date of the prospectus supplement is August 8, 2024.

HOOKIPA Pharma Inc. has announced an Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $50,000,000 of common stock. The agreement permits HOOKIPA Pharma to offer and sell its common stock through Jefferies, acting as a sales agent or principal. The previous sales agreement with SVB Securities LLC has been terminated, and no further sales will occur under that agreement. HOOKIPA Pharma's common stock is listed on the Nasdaq Capital Market under the symbol 'HOOK,' with a last reported sale price of $4.91 per share as of August 7, 2024. The sales are to be made in 'at the market offerings,' and Jefferies will receive a commission of 3.0% of the gross proceeds from any sales made under the agreement. Jefferies will also be considered an 'underwriter' within the meaning of the Securities Act, and will receive underwriting commissions or discounts. HOOKIPA Pharma has agreed to indemnify Jefferies against certain liabilities, including those under the Securities Act. The date of the prospectus supplement is August 8, 2024.